Cargando…

mTORC1-Inhibition Potentiating Metabolic Block by Tyrosine Kinase Inhibitor Ponatinib in Multiple Myeloma

SIMPLE SUMMARY: From a screen for metabolic inhibition by a panel of approved anticancer drugs and combining the lead compound with a mammalian target of rapamycin complex 1 (mTORC1) inhibitor, we demonstrated that the combination of ponatinib and sirolimus leads to synergistic tumor growth inhibiti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nazim, Uddin Md., Bishayee, Kausik, Kang, Jieun, Yoo, Dongkwan, Huh, Sung-Oh, Sadra, Ali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179535/ https://www.ncbi.nlm.nih.gov/pubmed/35681744 http://dx.doi.org/10.3390/cancers14112766

Ejemplares similares

RNA binding protein HuD promotes autophagy and tumor stress survival by suppressing mTORC1 activity and augmenting ARL6IP1 levels
por: Bishayee, Kausik, et al.
Publicado: (2022)

Correction to: RNA binding protein HuD promotes autophagy and tumor stress survival by suppressing mTORC1 activity and augmenting ARL6IP1 levels
por: Bishayee, Kausik, et al.
Publicado: (2022)

RNA Binding Protein Rbms1 Enables Neuronal Differentiation and Radial Migration during Neocortical Development by Binding and Stabilizing the RNA Message for Efr3a
por: Habib, Khadija, et al.
Publicado: (2022)

Farnesylation-defective Rheb Increases Axonal Length Independently of mTORC1 Activity in Embryonic Primary Neurons
por: Choi, Seunghyuk, et al.
Publicado: (2019)

Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
por: Zeng, Peng, et al.
Publicado: (2020)

Combination of mTOR and EGFR Kinase Inhibitors Blocks mTORC1 and mTORC2 Kinase Activity and Suppresses the Progression of Colorectal Carcinoma
por: Wang, Quan, et al.
Publicado: (2013)

Azoxystrobin Impairs Neuronal Migration and Induces ROS Dependent Apoptosis in Cortical Neurons
por: Kang, Jieun, et al.
Publicado: (2021)

Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
por: Tan, Fiona H, et al.
Publicado: (2019)

Autophagic flux inhibition enhances cytotoxicity of the receptor tyrosine kinase inhibitor ponatinib
por: Corallo, Diana, et al.
Publicado: (2020)

Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo
por: Yu, Tao, et al.
Publicado: (2021)

Focal Segmental Sclerosis Associated with the Novel Multi-tyrosine Kinase Inhibitor Ponatinib
por: Arai, Hiroyuki, et al.
Publicado: (2023)

mTORC1 and mTORC2 in cancer and the tumor microenvironment
por: Kim, Laura C., et al.
Publicado: (2016)

Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension
por: Tang, Haiyang, et al.
Publicado: (2018)

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib
por: Cassuto, Ophélie, et al.
Publicado: (2012)

Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion
por: Chen, Long, et al.
Publicado: (2015)

The metabolic waste ammonium regulates mTORC2 and mTORC1 signaling
por: Merhi, Ahmad, et al.
Publicado: (2017)

Angelica polymorpha Maxim Induces Apoptosis of Human SH-SY5Y Neuroblastoma Cells by Regulating an Intrinsic Caspase Pathway
por: Rahman, Md. Ataur, et al.
Publicado: (2016)

mTORC1 and mTORC2 regulate skin morphogenesis and epidermal barrier formation
por: Ding, Xiaolei, et al.
Publicado: (2016)

LPS Induces mTORC1 and mTORC2 Activation During Monocyte Adhesion
por: Ribeiro, Marcelle C., et al.
Publicado: (2018)

mTORC1 and mTORC2 differentially promote natural killer cell development
por: Yang, Chao, et al.
Publicado: (2018)

mTORC1 and mTORC2 are differentially engaged in the development of laser-induced CNV
por: Yang, Jin Young, et al.
Publicado: (2019)

Dopamine neuron morphology and output are differentially controlled by mTORC1 and mTORC2
por: Kosillo, Polina, et al.
Publicado: (2022)

Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways
por: Wang, Yan, et al.
Publicado: (2018)

Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2
por: Luo, Yan, et al.
Publicado: (2015)

mTORC2 contributes to the metabolic reprogramming in EGFR tyrosine-kinase inhibitor resistant cells in non-small cell lung cancer
por: Chiang, Chun-Te, et al.
Publicado: (2018)

Regulation of Autophagy through TORC1 and mTORC1
por: Noda, Takeshi
Publicado: (2017)

Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry
por: Rogers-Broadway, Karly-Rai, et al.
Publicado: (2019)

mTOR has a developmental stage-specific role in mitochondrial fitness independent of conventional mTORC1 and mTORC2 and the kinase activity
por: Kalim, Khalid W., et al.
Publicado: (2017)

An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma
por: Darawshi, Odai, et al.
Publicado: (2022)

A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma
por: Bendell, Johanna C., et al.
Publicado: (2015)

Glutaminolysis feeds mTORC1
por: Durán, Raúl V., et al.
Publicado: (2012)

Regulation of adiposity by mTORC1
por: Magdalon, Juliana, et al.
Publicado: (2017)

Regulation of mTORC2 Signaling
por: Fu, Wenxiang, et al.
Publicado: (2020)

mTORC2 Steals the Spotlight
por: Jansen, Laura A.
Publicado: (2020)

Something to mTORC About in NASH
por: Finck, Brian N.
Publicado: (2022)

Development of an RHEB-Targeting Peptide To Inhibit mTORC1 Kinase Activity
por: Shams, Raef, et al.
Publicado: (2022)

mTORC2, but not mTORC1, is required for hippocampal mGluR-LTD and associated behaviors
por: Zhu, Ping Jun, et al.
Publicado: (2018)

Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines
por: Lu, Liu, et al.
Publicado: (2018)

Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia
por: Kantarjian, Hagop M., et al.
Publicado: (2022)

S153: MECHANISMS OF TROMBOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDER TREATMENT WITH PONATINIB AND OTHER TYROSINE KINASE INHIBITORS
por: José Cuenca Zamora, Ernesto, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nikgmd89ojqj852f9ikm9vectl